Skip to main content
Top
Gepubliceerd in: Journal of Autism and Developmental Disorders 12/2021

07-09-2021 | Commentary

Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder

Auteurs: Erin Henneberry, Martine Lamy, Kelli C. Dominick, Craig A. Erickson

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 12/2021

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of interfering behavior has progressed in our field, there remain several areas of unmet medical need including most prominently a lack of any approved drug therapies for the core, defining symptoms of autism. We outline the progress to date in the field of autism drug treatment while taking a future look forward into how decades of work can inform better future steps in this field.
Literatuur
go back to reference Aoki, Y., Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., & Yamasue, H. (2015). Oxytocin’s neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: A randomized controlled trial. Molecular Psychiatry, 20(4), 447–453. https://doi.org/10.1038/mp.2014.74CrossRefPubMed Aoki, Y., Watanabe, T., Abe, O., Kuwabara, H., Yahata, N., Takano, Y., & Yamasue, H. (2015). Oxytocin’s neurochemical effects in the medial prefrontal cortex underlie recovery of task-specific brain activity in autism: A randomized controlled trial. Molecular Psychiatry, 20(4), 447–453. https://​doi.​org/​10.​1038/​mp.​2014.​74CrossRefPubMed
go back to reference Appleton, R. E., Jones, A. P., Gamble, C., Williamson, P. R., Wiggs, L., Montgomery, P., & Gringras, P. (2012). The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: A randomised, double-blind, placebo-controlled, parallel study (MENDS). Health Technology Assessment, 16(40), i239. https://doi.org/10.3310/hta16400CrossRef Appleton, R. E., Jones, A. P., Gamble, C., Williamson, P. R., Wiggs, L., Montgomery, P., & Gringras, P. (2012). The use of MElatonin in children with neurodevelopmental disorders and impaired sleep: A randomised, double-blind, placebo-controlled, parallel study (MENDS). Health Technology Assessment, 16(40), i239. https://​doi.​org/​10.​3310/​hta16400CrossRef
go back to reference Bachenberg, K. L. (1998). Oral ketamine for the management of combative autistic adult. Anesthesiology, 89(2), 549–550.CrossRef Bachenberg, K. L. (1998). Oral ketamine for the management of combative autistic adult. Anesthesiology, 89(2), 549–550.CrossRef
go back to reference Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., & Hagerman, R. J. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science Translational Medicine, 4(152), 152–127. https://doi.org/10.1126/scitranslmed.3004214CrossRef Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., & Hagerman, R. J. (2012). Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science Translational Medicine, 4(152), 152–127. https://​doi.​org/​10.​1126/​scitranslmed.​3004214CrossRef
go back to reference Bolognani, F., Del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., & Fontoura, P. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine, 11(491), 7838. https://doi.org/10.1126/scitranslmed.aat7838CrossRef Bolognani, F., Del Valle Rubido, M., Squassante, L., Wandel, C., Derks, M., Murtagh, L., & Fontoura, P. (2019). A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Science Translational Medicine, 11(491), 7838. https://​doi.​org/​10.​1126/​scitranslmed.​aat7838CrossRef
go back to reference Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004). Diabetes Care, 27(2), 596–601. Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004). Diabetes Care, 27(2), 596–601.
go back to reference Dean, O. M., Gray, K. M., Villagonzalo, K. A., Dodd, S., Mohebbi, M., Vick, T., & Berk, M. (2017). A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry, 51(3), 241–249. https://doi.org/10.1177/0004867416652735CrossRef Dean, O. M., Gray, K. M., Villagonzalo, K. A., Dodd, S., Mohebbi, M., Vick, T., & Berk, M. (2017). A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder. Australian and New Zealand Journal of Psychiatry, 51(3), 241–249. https://​doi.​org/​10.​1177/​0004867416652735​CrossRef
go back to reference Fankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. The Journal of Clinical Psychiatry, 53(3), 77–82.PubMed Fankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. The Journal of Clinical Psychiatry, 53(3), 77–82.PubMed
go back to reference Gencer, O., Emiroglu, F. N., Miral, S., Baykara, B., Baykara, A., & Dirik, E. (2008). Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. European Child & Adolescent Psychiatry, 17(4), 217–225. https://doi.org/10.1007/s00787-007-0656-6CrossRef Gencer, O., Emiroglu, F. N., Miral, S., Baykara, B., Baykara, A., & Dirik, E. (2008). Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. European Child & Adolescent Psychiatry, 17(4), 217–225. https://​doi.​org/​10.​1007/​s00787-007-0656-6CrossRef
go back to reference Handen, B. L., Anagnostou, E., Aman, M. G., Sanders, K. B., Chan, J., Hollway, J. A., & Veenstra-VanderWeele, J. (2017). A Randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: Open-label extension. Journal of the American Academy of Child and Adolescent Psychiatry, 56(10), 849-856.e846. https://doi.org/10.1016/j.jaac.2017.07.790CrossRefPubMed Handen, B. L., Anagnostou, E., Aman, M. G., Sanders, K. B., Chan, J., Hollway, J. A., & Veenstra-VanderWeele, J. (2017). A Randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: Open-label extension. Journal of the American Academy of Child and Adolescent Psychiatry, 56(10), 849-856.e846. https://​doi.​org/​10.​1016/​j.​jaac.​2017.​07.​790CrossRefPubMed
go back to reference Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.CrossRef Handen, B. L., Johnson, C. R., & Lubetsky, M. (2000). Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. Journal of Autism and Developmental Disorders, 30(3), 245–255.CrossRef
go back to reference Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., & Hoekstra, P. J. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(7), 733–741. https://doi.org/10.1016/j.jaac.2012.04.011CrossRefPubMed Harfterkamp, M., van de Loo-Neus, G., Minderaa, R. B., van der Gaag, R. J., Escobar, R., Schacht, A., & Hoekstra, P. J. (2012). A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 51(7), 733–741. https://​doi.​org/​10.​1016/​j.​jaac.​2012.​04.​011CrossRefPubMed
go back to reference Herscu, P., Handen, B. L., Arnold, L. E., Snape, M. F., Bregman, J. D., Ginsberg, L., & Autism Speaks Autism Clinical Trials, N. (2020). The SOFIA study: Negative multi-center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders, 50(9), 3233–3244. https://doi.org/10.1007/s10803-019-04120-yCrossRefPubMed Herscu, P., Handen, B. L., Arnold, L. E., Snape, M. F., Bregman, J. D., Ginsberg, L., & Autism Speaks Autism Clinical Trials, N. (2020). The SOFIA study: Negative multi-center study of low dose fluoxetine on repetitive behaviors in children and adolescents with autistic disorder. Journal of Autism and Developmental Disorders, 50(9), 3233–3244. https://​doi.​org/​10.​1007/​s10803-019-04120-yCrossRefPubMed
go back to reference Hollander, E., Dolgoff-Kaspar, R., Cartwright, C., Rawitt, R., & Novotny, S. (2001). An open trial of divalproex sodium in autism spectrum disorders. The Journal of Clinical Psychiatry, 62(7), 530–534.CrossRef Hollander, E., Dolgoff-Kaspar, R., Cartwright, C., Rawitt, R., & Novotny, S. (2001). An open trial of divalproex sodium in autism spectrum disorders. The Journal of Clinical Psychiatry, 62(7), 530–534.CrossRef
go back to reference Jaselskis, C. A., Cook, E. H., Jr., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322–327.CrossRef Jaselskis, C. A., Cook, E. H., Jr., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12(5), 322–327.CrossRef
go back to reference Kruppa, J. A., Gossen, A., Oberwelland Weiß, E., Kohls, G., Großheinrich, N., Cholemkery, H., & Schulte-Rüther, M. (2019). Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: A randomized trial. Neuropsychopharmacology, 44(4), 749–756. https://doi.org/10.1038/s41386-018-0258-7CrossRefPubMed Kruppa, J. A., Gossen, A., Oberwelland Weiß, E., Kohls, G., Großheinrich, N., Cholemkery, H., & Schulte-Rüther, M. (2019). Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with high-functioning autism spectrum disorder: A randomized trial. Neuropsychopharmacology, 44(4), 749–756. https://​doi.​org/​10.​1038/​s41386-018-0258-7CrossRefPubMed
go back to reference Kumar, B., Prakash, A., Sewal, R. K., Medhi, B., & Modi, M. (2012). Drug therapy in autism: a present and future perspective. Pharmacological Reports, 64(6), 1291–1304.CrossRef Kumar, B., Prakash, A., Sewal, R. K., Medhi, B., & Modi, M. (2012). Drug therapy in autism: a present and future perspective. Pharmacological Reports, 64(6), 1291–1304.CrossRef
go back to reference Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. https://doi.org/10.1097/CHI.0b013e3181b76658CrossRefPubMed Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, M. G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48(11), 1110–1119. https://​doi.​org/​10.​1097/​CHI.​0b013e3181b76658​CrossRefPubMed
go back to reference Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., & Findling, R. L. (2011). Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. Journal of Clinical Psychiatry, 72(9), 1270–1276. https://doi.org/10.4088/JCP.09m05933CrossRef Marcus, R. N., Owen, R., Manos, G., Mankoski, R., Kamen, L., McQuade, R. D., & Findling, R. L. (2011). Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. Journal of Clinical Psychiatry, 72(9), 1270–1276. https://​doi.​org/​10.​4088/​JCP.​09m05933CrossRef
go back to reference Martin, A., Koenig, K., Anderson, G. M., & Scahill, L. (2003). Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders, 33(1), 77–85.CrossRef Martin, A., Koenig, K., Anderson, G. M., & Scahill, L. (2003). Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders, 33(1), 77–85.CrossRef
go back to reference McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53(11), 1001–1008.CrossRef McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53(11), 1001–1008.CrossRef
go back to reference Mintz, M., & Hollenberg, E. (2019). Revisiting lithium: Utility for behavioral stabilization in adolescents and adults with autism spectrum disorder. Psychopharmacology Bulletin, 49(2), 28–40.PubMedPubMedCentral Mintz, M., & Hollenberg, E. (2019). Revisiting lithium: Utility for behavioral stabilization in adolescents and adults with autism spectrum disorder. Psychopharmacology Bulletin, 49(2), 28–40.PubMedPubMedCentral
go back to reference Ngamsamut, N., Hongkaew, Y., Vanwong, N., Srisawasdi, P., Puangpetch, A., Chamkrachangpada, B., & Sukasem, C. (2016). 9-Hydroxyrisperidone-induced hyperprolactinaemia in thai children and adolescents with autism spectrum disorder. Basic & Clinical Pharmacology & Toxicology, 119(3), 267–272. https://doi.org/10.1111/bcpt.12570CrossRef Ngamsamut, N., Hongkaew, Y., Vanwong, N., Srisawasdi, P., Puangpetch, A., Chamkrachangpada, B., & Sukasem, C. (2016). 9-Hydroxyrisperidone-induced hyperprolactinaemia in thai children and adolescents with autism spectrum disorder. Basic & Clinical Pharmacology & Toxicology, 119(3), 267–272. https://​doi.​org/​10.​1111/​bcpt.​12570CrossRef
go back to reference Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., & Cook, E. H., Jr. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517–524. https://doi.org/10.1089/cap.2006.16.517CrossRefPubMed Owley, T., Salt, J., Guter, S., Grieve, A., Walton, L., Ayuyao, N., & Cook, E. H., Jr. (2006). A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 517–524. https://​doi.​org/​10.​1089/​cap.​2006.​16.​517CrossRefPubMed
go back to reference Persico, A. M., Ricciardello, A., Lamberti, M., Turriziani, L., Cucinotta, F., Brogna, C., & Arango, C. (2021). The pediatric psychopharmacology of autism spectrum disorder: A systematic review—Part I: The past and the present. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 110, 110326. https://doi.org/10.1016/j.pnpbp.2021.110326CrossRef Persico, A. M., Ricciardello, A., Lamberti, M., Turriziani, L., Cucinotta, F., Brogna, C., & Arango, C. (2021). The pediatric psychopharmacology of autism spectrum disorder: A systematic review—Part I: The past and the present. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 110, 110326. https://​doi.​org/​10.​1016/​j.​pnpbp.​2021.​110326CrossRef
go back to reference Pretzsch, C. M., Freyberg, J., Voinescu, B., Lythgoe, D., Horder, J., Mendez, M. A., & McAlonan, G. M. (2019a). Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology, 44(8), 1398–1405. https://doi.org/10.1038/s41386-019-0333-8CrossRefPubMedPubMedCentral Pretzsch, C. M., Freyberg, J., Voinescu, B., Lythgoe, D., Horder, J., Mendez, M. A., & McAlonan, G. M. (2019a). Effects of cannabidiol on brain excitation and inhibition systems; a randomised placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder. Neuropsychopharmacology, 44(8), 1398–1405. https://​doi.​org/​10.​1038/​s41386-019-0333-8CrossRefPubMedPubMedCentral
go back to reference Pretzsch, C. M., Voinescu, B., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., & McAlonan, G. M. (2019b). The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology, 33(9), 1141–1148. https://doi.org/10.1177/0269881119858306CrossRefPubMed Pretzsch, C. M., Voinescu, B., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., & McAlonan, G. M. (2019b). The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). Journal of Psychopharmacology, 33(9), 1141–1148. https://​doi.​org/​10.​1177/​0269881119858306​CrossRefPubMed
go back to reference Purkayastha, P., Malapati, A., Yogeeswari, P., & Sriram, D. (2015). A review on GABA/glutamate pathway for therapeutic intervention of ASD and ADHD. Current Medicinal Chemistry, 22(15), 1850–1859.CrossRef Purkayastha, P., Malapati, A., Yogeeswari, P., & Sriram, D. (2015). A review on GABA/glutamate pathway for therapeutic intervention of ASD and ADHD. Current Medicinal Chemistry, 22(15), 1850–1859.CrossRef
go back to reference Reeves, G. M., Keeton, C., Correll, C. U., Johnson, J. L., Hamer, R. M., Sikich, L., & Riddle, M. A. (2013). Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: Rationale, design, and methods. Child and Adolescent Mental Health, 7(1), 31. https://doi.org/10.1186/1753-2000-7-31CrossRef Reeves, G. M., Keeton, C., Correll, C. U., Johnson, J. L., Hamer, R. M., Sikich, L., & Riddle, M. A. (2013). Improving metabolic parameters of antipsychotic child treatment (IMPACT) study: Rationale, design, and methods. Child and Adolescent Mental Health, 7(1), 31. https://​doi.​org/​10.​1186/​1753-2000-7-31CrossRef
go back to reference Rezaei, V., Mohammadi, M. R., Ghanizadeh, A., Sahraian, A., Tabrizi, M., Rezazadeh, S. A., & Akhondzadeh, S. (2010). Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-PsychopharMacology & Biological Psychiatry, 34(7), 1269–1272. https://doi.org/10.1016/j.pnpbp.2010.07.005CrossRef Rezaei, V., Mohammadi, M. R., Ghanizadeh, A., Sahraian, A., Tabrizi, M., Rezazadeh, S. A., & Akhondzadeh, S. (2010). Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuro-PsychopharMacology & Biological Psychiatry, 34(7), 1269–1272. https://​doi.​org/​10.​1016/​j.​pnpbp.​2010.​07.​005CrossRef
go back to reference Roke, Y., Buitelaar, J. K., Boot, A. M., Tenback, D., & van Harten, P. N. (2012). Risk of hyperprolactinemia and sexual side effects in males 10–20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. Journal of Child and Adolescent Psychopharmacology, 22(6), 432–439. https://doi.org/10.1089/cap.2011.0109CrossRefPubMed Roke, Y., Buitelaar, J. K., Boot, A. M., Tenback, D., & van Harten, P. N. (2012). Risk of hyperprolactinemia and sexual side effects in males 10–20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. Journal of Child and Adolescent Psychopharmacology, 22(6), 432–439. https://​doi.​org/​10.​1089/​cap.​2011.​0109CrossRefPubMed
go back to reference Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A Meta-Analysis. CMAJ, 165(11), 1475–1488.PubMedPubMedCentral Schachter, H. M., Pham, B., King, J., Langford, S., & Moher, D. (2001). How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A Meta-Analysis. CMAJ, 165(11), 1475–1488.PubMedPubMedCentral
go back to reference Schoemakers, R. J., van Kesteren, C., van Rosmalen, J., Eussen, M., Dieleman, H. G., & Beex-Oosterhuis, M. M. (2019). No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months. Journal of Child and Adolescent Psychopharmacology, 29(3), 192–196. https://doi.org/10.1089/cap.2018.0111CrossRefPubMed Schoemakers, R. J., van Kesteren, C., van Rosmalen, J., Eussen, M., Dieleman, H. G., & Beex-Oosterhuis, M. M. (2019). No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months. Journal of Child and Adolescent Psychopharmacology, 29(3), 192–196. https://​doi.​org/​10.​1089/​cap.​2018.​0111CrossRefPubMed
go back to reference Siegel, M., Beresford, C. A., Bunker, M., Verdi, M., Vishnevetsky, D., Karlsson, C., & Smith, K. A. (2014). Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 24(7), 399–402. https://doi.org/10.1089/cap.2014.0019CrossRefPubMed Siegel, M., Beresford, C. A., Bunker, M., Verdi, M., Vishnevetsky, D., Karlsson, C., & Smith, K. A. (2014). Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology, 24(7), 399–402. https://​doi.​org/​10.​1089/​cap.​2014.​0019CrossRefPubMed
go back to reference Sochocky, N., & Milin, R. (2013). Second generation antipsychotics in Asperger’s Disorder and high functioning autism: A systematic review of the literature and effectiveness of meta-analysis. Current Clinical Pharmacology, 8(4), 370–379.CrossRef Sochocky, N., & Milin, R. (2013). Second generation antipsychotics in Asperger’s Disorder and high functioning autism: A systematic review of the literature and effectiveness of meta-analysis. Current Clinical Pharmacology, 8(4), 370–379.CrossRef
go back to reference Sprengers, J. J., van Andel, D. M., Zuithoff, N. P. A., Keijzer-Veen, M. G., Schulp, A. J. A., Scheepers, F. E., & Bruining, H. (2020). Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. Journal of the American Academy of Child and Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2020.07.888CrossRefPubMed Sprengers, J. J., van Andel, D. M., Zuithoff, N. P. A., Keijzer-Veen, M. G., Schulp, A. J. A., Scheepers, F. E., & Bruining, H. (2020). Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial. Journal of the American Academy of Child and Adolescent Psychiatry. https://​doi.​org/​10.​1016/​j.​jaac.​2020.​07.​888CrossRefPubMed
go back to reference Umbricht, D., Del Valle Rubido, M., Hollander, E., McCracken, J. T., Shic, F., Scahill, L., & Fontoura, P. (2017). A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a Receptor Antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology, 42(9), 1914–1923. https://doi.org/10.1038/npp.2016.232CrossRefPubMed Umbricht, D., Del Valle Rubido, M., Hollander, E., McCracken, J. T., Shic, F., Scahill, L., & Fontoura, P. (2017). A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a Receptor Antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacology, 42(9), 1914–1923. https://​doi.​org/​10.​1038/​npp.​2016.​232CrossRefPubMed
go back to reference Varni, J. W., Handen, B. L., Corey-Lisle, P. K., Guo, Z., Manos, G., Ammerman, D. K., & Mankoski, R. (2012). Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: A post hoc analysis of two controlled trials. Clinical Therapeutics, 34(4), 980–992. https://doi.org/10.1016/j.clinthera.2012.02.023CrossRefPubMed Varni, J. W., Handen, B. L., Corey-Lisle, P. K., Guo, Z., Manos, G., Ammerman, D. K., & Mankoski, R. (2012). Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: A post hoc analysis of two controlled trials. Clinical Therapeutics, 34(4), 980–992. https://​doi.​org/​10.​1016/​j.​clinthera.​2012.​02.​023CrossRefPubMed
go back to reference Wink, L. K., Reisinger, D. L., Horn, P., Shaffer, R. C., O’Brien, K., Schmitt, L., & Erickson, C. A. (2021). Brief report: Intranasal ketamine in adolescents and young adults with autism spectrum disorder-initial results of a randomized, controlled, crossover, pilot study. Journal of Autism and Developmental Disorders, 51(4), 1392–1399. https://doi.org/10.1007/s10803-020-04542-zCrossRefPubMed Wink, L. K., Reisinger, D. L., Horn, P., Shaffer, R. C., O’Brien, K., Schmitt, L., & Erickson, C. A. (2021). Brief report: Intranasal ketamine in adolescents and young adults with autism spectrum disorder-initial results of a randomized, controlled, crossover, pilot study. Journal of Autism and Developmental Disorders, 51(4), 1392–1399. https://​doi.​org/​10.​1007/​s10803-020-04542-zCrossRefPubMed
Metagegevens
Titel
Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder
Auteurs
Erin Henneberry
Martine Lamy
Kelli C. Dominick
Craig A. Erickson
Publicatiedatum
07-09-2021
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 12/2021
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-021-05237-9

Andere artikelen Uitgave 12/2021

Journal of Autism and Developmental Disorders 12/2021 Naar de uitgave

S.I.: Autism in Review: 1980-2020: 40 years after DSM-III

Epidemiological surveys of ASD: advances and remaining challenges

S:I Autism in Review: 1980-2020: 40 years after DSM-III

The Diagnosis of Autism: From Kanner to DSM-III to DSM-5 and Beyond